Medicover Genetics proudly celebrates ten years of VERACITY, the new generation non-invasive prenatal test (NIPT) designed, developed, and validated by Cypriot scientists. Since its introduction to the medical community in 2015, VERACITY has grown into a trusted global standard for safe, accurate, and clinically meaningful prenatal screening.
Developed by a team of leading geneticists and researchers in Cyprus, VERACITY represents a landmark in the advancement of genetic medicine. Using advanced cell-free DNA analysis, the test offers expectant parents a reliable and completely safe way to screen for common chromosomal conditions such as Down, Edwards, and Patau syndromes, as well as other clinically important genetic syndromes. “This ten-year milestone is a testament to the pursuit of excellence in science,” said Dr Marios Ioannides, Managing Director of Medicover Genetics, Cyprus. “From concept to clinical impact, VERACITY demonstrates how innovation can shape global prenatal clinical practice.”
A Decade of Clinical and Scientific Excellence
With over hundreds of thousands of tests performed in more than 60 countries, VERACITY has become one of the most trusted non-invasive prenatal tests worldwide. Available from as early as the 9th week of pregnancy and processed in CAP-accredited and ISO-certified laboratories, the test has been validated for singleton, twin, IVF, and vanishing twin pregnancies and demonstrates sensitivity and specificity above 99% for common trisomies.
Building on this proven performance, both VERACITY and VERAgene NIPTs now include screening for 3 additional microdeletion syndromes: Prader–Willi, Angelman, and Cri-du-chat syndromes, providing broader insight into clinically relevant and rare genetic conditions.
VERACITY’s panel, performance, and methodology align with the latest international guidelines for non-invasive prenatal testing. Leading professional bodies including ACOG, SMFM, ISPD, and ACMG recommend that NIPT be offered to all pregnant women, regardless of age or risk, as the most accurate and reliable screening method for common trisomies, a standard fully met by VERACITY’s accredited methodology.
Cyprus at the Heart of Genetic Innovation
VERACITY’s success highlights Cyprus as an emerging hub of biomedical innovation. From its development and validation to its global expansion under Medicover Genetics, this Cypriot-led initiative demonstrates how local scientific excellence can achieve international trust and reach.
“The VERACITY technology platform showcases Cyprus’s ability to lead in specialized scientific fields,” added Dr Ioannides. “Our team’s expertise and dedication have placed Cyprus on the global map of biotechnology innovation.”
Looking to the Future: Building the Next Chapter
As Medicover Genetics enters the next decade, the company remains committed to advancing science with the same values that have defined its first ten years: trust, precision, and care.
Building on VERACITY’s legacy in cell-free genomics, Medicover Genetics is expanding its scientific expertise into the field of oncology diagnostics. Active research programs are focused on the development of next-generation assays, including liquid-biopsy technology platform, which have the potential to transform how cancer is detected, monitored, and treated – ultimately improving patient outcomes.
Both VERACITY and VERAgene NIPTs are screening tests, not diagnostic tests. A high-risk result should always be confirmed by invasive diagnostic testing, such as amniocentesis, before clinical decisions are made.
For more information visit https://medicover-genetics.com/our-genetic-tests/reproductive-health/nipt/